Physician profile
Charles Borum
NPI 1417042979
$2,310.68
in general payments reported to CMS, 2019-2025
27 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $806 · 2021: $337 · 2022: $205 · 2023: $339 · 2024: $99.58 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $478.54 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $316.75 | 2020-2025 | Verquvo, Belsomra |
| Lilly USA, LLC | $165.13 | 2019-2024 | Mounjaro |
| Novo Nordisk INC | $151.29 | 2019-2022 | |
| Glaxosmithkline, LLC. | $121.53 | 2020-2021 | |
| Abbvie INC. | $110.02 | 2020-2025 | Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.31 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $95.32 | 2020-2025 | Breztri |
| Allergan, INC. | $86.43 | 2020 | |
| Phathom Pharmaceuticals, INC. | $83.01 | 2025 | Voquezna |
| Fidia Pharma USA INC. | $72.31 | 2019-2021 | |
| Amgen INC. | $68.66 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $63.49 | 2019-2021 | |
| Abbott Laboratories | $63.34 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $56.47 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $51.90 | 2023 | Nuplazid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.22 | 2020-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $23.30 | 2022 | |
| Sk Life Science, INC. | $22.97 | 2021 | |
| Abiomed | $21.93 | 2025 | |
| Exact Sciences Corporation | $21.19 | 2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $20.81 | 2020 | |
| Mylan Specialty L.P. | $19.95 | 2020 | |
| Currax Pharmaceuticals LLC | $18.16 | 2025 | Contrave |
| Astellas Pharma US INC | $18.16 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.87 | 2019 | |
| Sanofi Pasteur INC. | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Borum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.